We can’t show the full text here under this license. Use the link below to read it at the source.
Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
Does gut bacteria transfer improve cancer immunotherapy? A combined analysis of microbiota transplants and immune checkpoint treatments
AI simplified
Abstract
The pooled objective response rate (ORR) for combining fecal microbiota transplantation (FMT) with immune checkpoint inhibitors (ICIs) was 43%.
- Subgroup analysis indicated a higher ORR of 60% when combining anti-PD-1 and anti-CTLA-4 therapies compared to a 37% ORR with anti-PD-1 alone.
- Grade 1-2 adverse events occurred in 42% of patients, while grade 3-4 adverse events were reported in 37%.
- This analysis included 10 studies with a total of 164 patients with solid tumors.
- Preliminary evidence suggests that FMT may enhance the efficacy of ICIs in treating advanced or refractory solid tumors.
- Further research is needed, including larger-scale randomized controlled trials, to confirm these findings and improve treatment protocols.
AI simplified
Key numbers
43%
Objective Response Rate (ORR)
Pooled ORR from the analysis of 10 studies.
42%
Grade 1-2 Adverse Events (AEs)
Incidence of grade 1-2 AEs in patients receiving FMT with ICIs.
37%
Grade 3-4 Adverse Events (AEs)
Incidence of grade 3-4 AEs in patients receiving FMT with ICIs.